Reata Pharmaceuticals’ Product Omaveloxolone Met the Trial Primary Endpoints in Treating Friedreich’s Ataxia
October 16, 2019
0
Reata Pharmaceuticals Omaveloxolone for Friedreich’s Ataxia On October 14, 2019 Reata Pharmaceuticals (RETA) announced the Part 2 portion of its Phase 2 MOXIe trial, with its product omaveloxolone, met its primary endpoint in modifying Friedreich’s ataxia (FA). The largest change occurred in the modified Friedreich’s Ataxia Rating Scale (mFARS) after 48 weeks of treatment. Patients treated with omaveloxolone 150 mg/day demonstrated …
